Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Leap Therapeutics (LPTX – Research Report) today and set a price target of $20.00. The company’s shares opened today at $2.36.
According to TipRanks, Goldstein is an analyst with an average return of -4.9% and a 33.47% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Iovance Biotherapeutics, and Merck & Company.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Leap Therapeutics with a $23.00 average price target.
See the top stocks recommended by analysts >>
LPTX market cap is currently $28.18M and has a P/E ratio of -0.33.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01 and TRX518. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
Read More on LPTX:
- Leap Therapeutics Reports Second Quarter 2023 Financial Results
- LPTX Upcoming Earnings Report: What to Expect?
- Leap Therapeutics initiates Part B of the DeFianCe study of DKN-01
- Biotech Alert: Searches spiking for these stocks today
- Leap Therapeutics price target lowered to $17 from $20 at Raymond James
